One of the big winners in the health-care space on Friday was Illumina (NASDAQ:ILMN), up 10% for the day after the company outlined its strategic vision. The big news from the report was its new genome sequencer machine, designed to process a staggering 20,000 genomes a year, at a price point of $1,000. This price has long been a target for the industry, and Illumina's reaching it should lead to widespread use of its machine. Releasing its sequencer now also gets it out ahead of competitor Life Technologies' (UNKNOWN:UNKNOWN) $1,000 sequencer, and it positions Illumina to dominate what could be a $20 billion market. In this video, Fool health-care analyst David Williamson tells investors just how big the potential for Illumina in this space could be, and what to watch for from here.
- Jan 18, 2014 at 5:24PM
- Health Care